The same MRI scan can cost $350 at one facility and $2,500 at another. For Mark Cuban, that gap is not just a pricing anomaly. It is the defining symbol of everything broken about American healthcare. The billionaire entrepreneur and Cost Plus Drugs co-founder has laid out a vision for what a functional healthcare system could look like, and his answer is far simpler than the industry might prefer to hear.
The case for going back to basics
In a post on his personal blog, Cuban argued that the American healthcare system has buried what should be a straightforward transaction beneath an almost incomprehensible stack of contracts, billing systems and insurance bureaucracy. His proposed model strips it down to its most essential form: a patient receives care, a provider delivers it, a bill is issued and the patient pays what they can afford. That is the entire transaction. No intermediaries, no opaque negotiated rates, no prior authorizations.
Cuban was careful to clarify that his critique is not directed at medical innovation or the ongoing effort to improve patient outcomes. Advances in surgical technology, pharmaceuticals and diagnostics are, in his view, genuinely valuable. What he objects to is a separate phenomenon: the construction of complexity for its own sake, where the administrative apparatus around healthcare has become a profit center entirely independent of actual care delivery.
Where the money actually goes
Cuban’s analysis starts with the roughly $5 trillion Americans spend on healthcare annually and works backward through the system to find where the money disappears before it reaches patients. His estimates point to administrative costs consuming between 20 and 30 percent of total spending, a figure he attributes largely to the ongoing billing conflicts between insurance companies, providers and patients. Layer on top of that an estimated 10 percent lost to fraud, overbilling and the practice of upcoding, where procedures are billed at higher complexity levels than the care actually provided warrants, and the waste compounds significantly.
The arithmetic leads Cuban to an estimate of roughly $2.5 trillion in potential annual savings if the system were substantially more transparent and direct payment models became the norm rather than the exception. That figure is not a precise projection but a rough illustration of the scale of inefficiency he believes the current structure generates.
The transparency argument
Central to Cuban’s proposal is the idea that healthcare pricing must become genuinely readable and publicly available, not the performative transparency of thousand-page documents no one can interpret. He advocates for a straightforward breakdown of actual costs, covering everything from the supplies used in a procedure to the fees charged by each medical professional involved, presented in a format patients can actually understand and compare.
He also argues that healthcare contracts between insurers and providers should be made public. Currently those contracts are treated as proprietary, which means patients have no way of knowing what their insurer has negotiated on their behalf or whether the resulting rates are reasonable. Publishing those agreements, in his view, is what would finally allow market forces to function in a sector where price signals are almost entirely hidden.
The cash-pay reality strengthens his argument. Multiple studies have found that patients who pay out of pocket for medical services, bypassing insurance entirely, regularly receive discounts ranging from 20 to 70 percent compared to what insured patients are billed. That dynamic suggests the posted prices in the current system bear little relationship to the actual cost of care.
The investment angle Cuban sees in all of this
Healthcare represents roughly 18 percent of the entire U.S. economy, yet consumers navigate it with less pricing information than they have when booking a flight. Cuban‘s own Cost Plus Drugs, which publishes the actual cost and markup of prescription medications, is a direct application of his transparency philosophy to pharmaceutical pricing. His broader argument is that whoever makes healthcare easier to understand, compare and pay for stands to gain significantly if transparency becomes an industry expectation rather than an outlier business model.
Source: Barchart, as reported June 6, 2026. This article is for informational purposes only and does not constitute financial or medical advice.